References

BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia

10.3390/pharmaceutics14010215 · 2022 · External reference

European LeukemiaNet recommendations for the management of chronic myeloid leukemia

10.1038/s41375-025-02664-w · 2025 · External reference

Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial

10.1001/jamaoncol.2020.5774 · 2021 · External reference

Response and resistance to BCR-ABL1-Targeted therapies

10.1016/j.ccell.2020.03.006 · 2020 · External reference

Third-line therapy for chronic myeloid leukemia: current status and future directions

10.1186/s13045-021-01055-9 · 2021 · External reference

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial

10.1182/blood.2025029210 · 2026 · External reference

Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology

10.6004/jnccn.2020.0047 · 2020 · External reference

Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study

10.1016/s0140-6736(19)33220-9 · 2020 · External reference

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

10.1182/blood.2024026311 · 2025 · External reference

Asciminib in newly diagnosed chronic myeloid leukemia

10.1056/nejmoa2400858 · 2024 · External reference

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

10.1002/ajh.27443 · 2024 · External reference

Chronic myeloid leukemia: a review

10.1001/jama.2025.0220 · 2025 · External reference

Management of chronic myeloid leukemia in 2025

10.1002/cncr.35953 · 2025 · External reference

Evaluation of oncology trial results reporting over a 10-Year period

10.1001/jamanetworkopen.2021.10438 · 2021 · External reference

Do published data in trials assessing cancer drugs reflect the real picture of efficacy and safety?

10.6004/jnccn.2017.7002 · 2017 · External reference

Chronic myeloid leukemia: modern therapies, current challenges and future directions

10.1016/j.blre.2021.100825 · 2021 · External reference

Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology

10.6004/jnccn.2018.0071 · 2018 · External reference

Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology

10.6004/jnccn.2024.0007 · 2024 · External reference

Unresolved reference

2024 · External reference

Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis

10.1001/jamanetworkopen.2021.20165 · 2021 · External reference

Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?

10.1186/s12967-024-05882-5 · 2024 · External reference